The chronic use of glaucoma medications could improve the development of an ocular comorbidity, the glaucoma therapy-related ocular surface disease. This could be related to the exposure of the conjunctiva to preservatives, but also active compounds such as prostaglandin analogues may improve the risk of ocular surface inflammation. Inflammation has a negative impact on tolerability and adherence to eyedrops and to the outcome of filtration surgery as well. A stratification of glaucoma patients based not only on visual field progression but also on glaucoma therapy-related ocular surface disease would be desirable for a strategic management. Early diagnosis, individualized treatment, and safe surgical management should be the hallmarks of glaucoma treatment. One of the main issues for the proper and successful management of patients is the right timing, effectiveness and safety for both medical and surgical treatment options leading to a precision medicine in glaucoma disease as the best modern treatment.
ZhangNWangJLiY, et al.Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Sci Rep2021; 11: 13762.
2.
QuigleyHA. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol2006; 90: 262–267.
3.
ZhangNWangJChenB, et al.Prevalence of primary angle closure glaucoma in the last 20 years: a meta-analysis and systematic review. Front Med (Lausanne)2021; 7: 624179. DOI: 10.3389/fmed.2020.624179. eCollection 2020
4.
FosterPJ. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol2002; 86: 238–242.
5.
European glaucoma society terminology and guidelines for glaucoma, 4th edition - chapter 2: classification and terminology supported by the EGS foundation. Br J Ophthalmol2017; 101: 73–127.
6.
NijmLMde Benito-LlopisLRossiGC, et al.Understanding the dual dilemma of dry eye and glaucoma: an international review. Asia-Pacific Journal of Ophthalmology2020; 9: 481–490.
7.
HollóGKatsanosABoboridisKG, et al.Preservative-Free prostaglandin analogs and prostaglandin/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs2018; 78: 39–64.
8.
PflugfelderSCBaudouinC. Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clin Ophthalmol2011; 5: 1575–1583.
9.
BaudouinCAragonaPMessmerEM, et al.Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf2013; 11: 246–258.
10.
MeloniMPaulyAde ServiB, et al.Occludin gene expression as an early in vitro sign for mild eye irritation assessment. Toxicol in Vitro2010; 24: 276–285.
BaudouinC. Ocular Surface and External Filtration Surgery: Mutual Relationships. 2012, pp. 64–78.
13.
AgnifiliLBresciaLOddoneF, et al.The ocular surface after successful glaucoma filtration surgery: a clinical, in vivo confocal microscopy, and immune-cytology study. Sci Rep2019; 9: 11299.
FigusMAgnifiliLLanziniM, et al.Topical preservative-free ophthalmic treatments: an unmet clinical need. Expert Opin Drug Deliv2021; 18: 655–672.
16.
BaudouinCNordmannJ-PDenisP, et al.Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefe’s Archive for Clinical and Experimental Ophthalmology2002; 240: 929–935.
17.
BreusegemCSpielbergLvan GinderdeurenR, et al.Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy. Ophthalmology2010; 117: 1324–1330.
18.
BaudouinCKolkoMMelik-ParsadaniantzS, et al.Inflammation in glaucoma: from the back to the front of the eye, and beyond. Prog Retin Eye Res2021; 83: 100916.
19.
BelamkarAHarrisAZukermanR, et al.Sustained release glaucoma therapies: novel modalities for overcoming key treatment barriers associated with topical medications. Ann Med2022; 54: 343–358.
20.
LingJDBellNP. Role of cataract surgery in the management of glaucoma. Int Ophthalmol Clin2018; 58: 87–100.
21.
Shokoohi-RadSKarimiFZarei-GhanavatiS, et al.Phacoemulsification, visco-goniosynechialysis, and goniotomy in patients with primary angle-closure glaucoma: a comparative study. Eur J Ophthalmol2021; 31: 88–95.
22.
MoghimiSLatifiGZandVakilN, et al.Phacoemulsification versus combined phacoemulsification and viscogonioplasty in primary angle-closure glaucoma. J Glaucoma2015; 24: 575–582.
23.
ThamCCYKwongYYYLeungDYL, et al.Phacoemulsification versus combined phacotrabeculectomy in medically controlled chronic angle closure glaucoma with cataract. Ophthalmology2008; 115: 2167–2173.e2.
24.
ThamCCYKwongYYYLeungDYL, et al.Phacoemulsification versus combined phacotrabeculectomy in medically uncontrolled chronic angle closure glaucoma with cataracts. Ophthalmology2009; 116: 725–731.e3.
25.
ThamCCYLeungDYLKwongYYY, et al.Effects of phacoemulsification versus combined phaco-trabeculectomy on drainage angle Status in primary angle closure glaucoma (PACG). J Glaucoma2010; 19: 119–123.
26.
ThamCCYKwongYYYBaigN, et al.Phacoemulsification versus trabeculectomy in medically uncontrolled chronic angle-closure glaucoma without cataract. Ophthalmology2013; 120: 62–67.
27.
HansapinyoLChoyBNKLaiJSM, et al.Phacoemulsification versus phacotrabeculectomy in primary angle-closure glaucoma with cataract. J Glaucoma2020; 29: 15–23.
28.
TeekhasaeneeC. Combined phacoemulsification and goniosynechialysis for uncontrolled chronic angle-closure glaucoma after acute angle-closure glaucoma. Ophthalmology1999; 106: 669–675.
29.
CostaVPLeungCKSKookMS, et al.Clear lens extraction in eyes with primary angle closure and primary angle-closure glaucoma. Surv Ophthalmol2020; 65: 662–674.
30.
HohbergerBWelge-LüßenU-CLämmerR. MIGS: therapeutic success of combined Xen gel stent implantation with cataract surgery. Graefe’s Archive for Clinical and Experimental Ophthalmology2018; 256: 621–625.
31.
LimR.The surgical management of glaucoma: a review. Clin Exp Ophthalmol2022; 50(2): 213–231. DOI: 10.1111/ceo.14028.
32.
WrightP. Squamous metaplasia or epidermalization of the conjunctiva as an adverse reaction to topical medication. Trans Ophthalmol Soc UK1979; 99: 244–246.
33.
SherwoodMBGriersonIMilgarL, et al.Long-term morphologic effects of antiglaucoma drugs on the Conjunctiva and tenon’s capsule in glaucomatous patients. Ophthalmology1989; 96: 327–335.
34.
BrandtJDWittpennJRKatzLJ, et al.Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol1991; 112: 297–301.
35.
HerrerasJMPastorJCCalongeM, et al.Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology1992; 99: 1082–1088.
MastropasquaRAgnifiliLFasanellaV, et al.Corneoscleral limbus in glaucoma patients: in vivo confocal microscopy and immunocytological study. Investigative Opthalmology & Visual Science2015; 56: 2050.
38.
MastropasquaRAgnifiliLFasanellaV, et al.In vivo distribution of corneal epithelial dendritic cells in patients with glaucoma. Investigative Opthalmology & Visual Science2016; 57: 5996.
39.
VillaniESacchiMMagnaniF, et al.The ocular surface in medically controlled glaucoma: an in vivo confocal study. Investigative Opthalmology & Visual Science2016; 57: 1003.
40.
BaudouinCLiangHHamardP, et al.The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology2008; 115: 109–115.
41.
FreedmanJIserovichP. Pro-Inflammatory cytokines in glaucomatous aqueous and encysted Molteno implant blebs and their relationship to pressure. Investigative Opthalmology & Visual Science2013; 54: 4851.
42.
TakaiYTanitoMOhiraA. Multiplex cytokine analysis of aqueous humor in eyes with primary open-angle glaucoma, exfoliation glaucoma, and cataract. Investigative Opthalmology & Visual Science2012; 53: 241.
43.
SacchiMAgnifiliLBresciaL, et al.Structural imaging of conjunctival filtering blebs in XEN gel implantation and trabeculectomy: a confocal and anterior segment optical coherence tomography study. Graefe’s Archive for Clinical and Experimental Ophthalmology2020; 258: 1763–1770.
AgnifiliLSacchiMFigusM, et al.Preparing the ocular surface for glaucoma filtration surgery: an unmet clinical need. Acta Ophthalmol2022; 100: 740–751. DOI: 10.1111/aos.15098.
46.
LandersJMartinKSarkiesN, et al.A twenty-year follow-up study of trabeculectomy: risk factors and outcomes. Ophthalmology2012; 119: 694–702.
47.
BoimerCBirtCM. Preservative exposure and surgical outcomes in glaucoma patients. J Glaucoma2013; 22: 730–735.
48.
BowdenECChoudhuryAGeddeSJ, et al.Risk factors for failure of tube shunt surgery: a pooled data analysis. Am J Ophthalmol2022; 240: 217–224.
49.
MyersJSLamraniRHallajS, et al.10-Year Clinical Outcomes of Tube Shunt Surgery at a Tertiary Care Center. Am J Ophthalmol2023; 253: 132–141. DOI: 10.1016/j.ajo.2023.04.001.
50.
BroadwayDCChangLP. Trabeculectomy, risk factors for failure and the preoperative state of the Conjunctiva. J Glaucoma2001; 10: 237–249.
51.
KhawPTChiangMShahP, et al.Enhanced trabeculectomy – the moorfields safer surgery system. 2012, pp. 1–28.
52.
European glaucoma society terminology and guidelines for glaucoma, 5th Edition. Br J Ophthalmol2021; 105: 1–169. DOI: 10.1136/bjophthalmol-2021-egsguidelines.
53.
HitchingsRAGriersonI. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc U K1983; 103(Pt 1): 84–88.
54.
BroadwayDCGriersonIHitchingsRA. Local effects of previous conjunctival incisional surgery and the subsequent outcome of filtration surgery. Am J Ophthalmol1998; 125: 805–818.
55.
LawSKShihKTranDH, et al.Long-term outcomes of repeat vs initial trabeculectomy in open-angle glaucoma. Am J Ophthalmol2009; 148: 685–695.e1.
56.
SugimotoYMochizukiHOhkuboS, et al.Intraocular pressure outcomes and risk factors for failure in the collaborative bleb-related infection incidence and treatment study. Ophthalmology2015; 122: 2223–2233.
57.
AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. risk factors for failure of trabeculectomy and argon laser trabeculoplasty. Am J Ophthalmol2002; 134: 481–498.
58.
IwaoKInataniMSetoT, et al.Long-term outcomes and prognostic factors for trabeculectomy with mitomycin C in eyes with uveitic glaucoma. J Glaucoma2014; 23: 88–94.
59.
KaburakiTKoshinoTKawashimaH, et al.Initial trabeculectomy with mitomycin C in eyes with uveitic glaucoma with inactive uveitis. Eye2009; 23: 1509–1517.
60.
TowlerHMABatesAKBroadwayDC, et al.Primary trabeculectomy with 5-fluorouracil for glaucoma secondary to uveitis. Ocul Immunol Inflamm1995; 3: 163–170.
61.
ParkU-CAhnJKParkKH, et al.Phacotrabeculectomy with mitomycin C in patients with uveitis. Am J Ophthalmol2006; 142: 1005–1012.
62.
NobleJDerzko-DzulynskyLRabinovitchT, et al.Outcome of trabeculectomy with intraoperative mitomycin C for uveitic glaucoma. Can J Ophthalmol2007; 42: 89–94.
63.
BroadwayDCBatesAKLightmanSL, et al.The importance of cellular changes in the conjunctiva of patients with uveitic glaucoma undergoing trabeculectomy. Eye (Lond)1993; 7: 495–501.
64.
StavrouPMurrayPI. Long-term follow-up of trabeculectomy without antimetabolites in patients with uveitis. Am J Ophthalmol1999; 128: 434–439.
65.
ShimizuAMaruyamaKYokoyamaY, et al.Characteristics of uveitic glaucoma and evaluation of its surgical treatment. Clinical Ophthalmology2014; 8: 2383–2389. DOI: 10.2147/OPTH.S72383.
66.
KwonHJKongYXGTaoLW, et al.Surgical outcomes of trabeculectomy and glaucoma drainage implant for uveitic glaucoma and relationship with uveitis activity. Clin Exp Ophthalmol2017; 45: 472–480.
67.
HelinMRönkköSPuustjärviT, et al.Conjunctival inflammatory cells and their predictive role for deep sclerectomy in primary open-angle glaucoma and exfoliation glaucoma. J Glaucoma2011; 20: 172–178.
68.
MastropasquaRFasanellaVBresciaL, et al.In vivo confocal imaging of the Conjunctiva as a predictive tool for the glaucoma filtration surgery outcome. Investigative Opthalmology & Visual Science2017; 58: BIO114.
69.
MastropasquaLBresciaLOddoneF, et al.Conjunctival thickness as a predictive imaging biomarker for the glaucoma filtration surgery outcome: an optical coherence tomography study. Clin Exp Ophthalmol2020; 48: 1192–1200.
70.
de BoerMRMollACde VetHCW, et al.Psychometric properties of vision-related quality of life questionnaires: a systematic review. Ophthalmic and Physiological Optics2004; 24: 257–273.
71.
MangioneCM. Development of the 25-list-item national eye institute visual function questionnaire. Arch Ophthalmol2001; 119: 1050.
72.
LeeBL. The glaucoma symptom scale. Arch Ophthalmol1998; 116: 861.
73.
GoldbergIClementCIChiangTH, et al.Assessing quality of life in patients with glaucoma using the glaucoma quality of life-15 (GQL-15) questionnaire. J Glaucoma2009; 18: 6–12.
74.
ParrishRK. Visual impairment, visual functioning, and quality of life assessments in patients with glaucoma. Trans Am Ophthalmol Soc1996; 94: 919–1028.
75.
RulliEQuarantaLRivaI, et al.Visual field loss and vision-related quality of life in the Italian primary open angle glaucoma study. Sci Rep2018; 8: 619.
76.
KumarSSinghTIchhpujaniP, et al.Correlation of ocular surface disease and quality of life in Indian glaucoma patients: BAC-preserved versus BAC-free travoprost. Turk J Ophthalmol2020; 50: 75–81.
77.
PaulsenAJCruickshanksKJFischerME, et al.Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol2014; 157: 799–806.
78.
RossiGCMPasinettiGMScudellerL, et al.Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther2013; 29: 390–394.
79.
EnochJJonesLTaylorDJ, et al.How do different lighting conditions affect the vision and quality of life of people with glaucoma? A systematic review. Eye2020; 34: 138–154.
80.
SagaraHSekiryuTImaizumiK, et al.Impact of tear metrics on the reliability of perimetry in patients with dry eye. PLoS One2019; 14: e0222467.
81.
QiuMWangSYSinghK, et al.Association between visual field defects and quality of life in the United States. Ophthalmology2014; 121: 733–740.
82.
WangYAlnwisiSKeM. The impact of mild, moderate, and severe visual field loss in glaucoma on patients’ quality of life measured via the glaucoma quality of life-15 questionnaire. Medicine (Baltimore)2017; 96: e8019.
83.
MarinoPRossiGCampagnaG, et al.Effects of citicoline, homotaurine, and vitamin E on contrast sensitivity and visual-related quality of life in patients with primary open-angle glaucoma: a preliminary study. Molecules2020; 25: 5614.
84.
ÖzyolPÖzyolEKaralezliA. Evaluation of visual field test parameters after artificial tear administration in patients with glaucoma and dry eye. Semin Ophthalmol2018; 33: 320–324.
85.
RossiGCMScudellerLRolleT, et al.From benzalkonium chloride-preserved latanoprost to polyquad-preserved travoprost: a 6-month study on ocular surface safety and tolerability. Expert Opin Drug Saf2015; 14: 619–623.
86.
RossiGCMScudellerLLuminiC, et al.An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy. Sci Rep2019; 9: 4282.
87.
BaudouinC.Ocular surface and external filtration surgery: mutual relationships. 2017, pp. 67–79.
88.
CvenkelBKopitarANIhanA. Correlation between filtering bleb morphology, expression of inflammatory marker HLA-DR by ocular surface, and outcome of trabeculectomy. J Glaucoma2013; 22: 15–20.
89.
JiHZhuYZhangY, et al.Dry eye disease in patients with functioning filtering blebs after trabeculectomy. PLoS One2016; 11: e0152696.
90.
BudenzDLHoffmanKZaccheiA. Glaucoma filtering bleb dysesthesia. Am J Ophthalmol2001; 131: 626–630.
91.
MastropasquaLAgnifiliLMastropasquaR, et al.Conjunctival modifications induced by medical and surgical therapies in patients with glaucoma. Curr Opin Pharmacol2013; 13: 56–64.
92.
AgnifiliLBresciaLOddoneF, et al.The ocular surface after successful glaucoma filtration surgery: a clinical, in vivo confocal microscopy, and immune-cytology study. Sci Rep2019; 9: 11299.
93.
FeaAMBronAMEconomouMA, et al.European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma. J Cataract Refract Surg2020; 46: 441–450.
94.
FeaAMLaffiGLMartiniE, et al.Effectiveness of MicroShunt in patients with primary open-angle and pseudoexfoliative glaucoma. Ophthalmol Glaucoma2022; 5: 210–218.
95.
SacchiMMonsellatoGVillaniE, et al.Intraocular pressure control after combined phacotrabeculectomy versus trabeculectomy alone. Eur J Ophthalmol2022; 32: 327–335.
96.
FrancisB. Characteristics of glaucoma drainage implants during dynamic and steady-state flow conditions. Ophthalmology1998; 105: 1708–1714.
97.
KangYKShinJPKimDW. Long-term surgical outcomes of Ahmed valve implantation in refractory glaucoma according to the type of glaucoma. BMC Ophthalmol2022; 22: 270.
98.
DaneshvarRKarimiFGolamiF, et al.Long-term comparison of the outcomes of Ahmed glaucoma valve surgery between glaucoma surgeons and cornea trained surgeons. Int Ophthalmol2022; 42: 1183–1191.
99.
MoltenoAC. New implant for drainage in glaucoma. Clinical Trial. British Journal of Ophthalmology1969; 53: 606–615.
100.
ShieldsMBScroggsMWSloopCM, et al.Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C. Am J Ophthalmol1993; 116: 673–683.
101.
SacuSRainerGFindlO, et al.Correlation between the early morphological appearance of filtering blebs and outcome of trabeculectomy with mitomycin C. J Glaucoma2003; 12: 430–435.
102.
VestiE. Filtering blebs: follow up of trabeculectomy. Ophthalmic Surg1993; 24: 249–255.
103.
PichtGGrehnF. Classification of filtering blebs in trabeculectomy: biomicroscopy and functionality. Curr Opin Ophthalmol1998; 9: 2–8.
104.
LavinMJ. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol1990; 108: 1543.
105.
LabbéADupasBHamardP, et al.In vivo confocal microscopy study of blebs after filtering surgery. Ophthalmology2005; 112: 1979.e1–1979.e9.
106.
GipsonIK. Distribution of mucins at the ocular surface. Exp Eye Res2004; 78: 379–388.
107.
ArgüesoPGipsonIK. Epithelial mucins of the ocular surface: structure, biosynthesis and function. Exp Eye Res2001; 73: 281–289.
108.
AmarNLabbéAHamardP, et al.Filtering blebs and aqueous pathway. Ophthalmology2008; 115: 1154–1161.e4.
109.
CarnevaleCRivaIRobertiG, et al.Confocal microscopy and anterior segment optical coherence tomography imaging of the ocular surface and bleb morphology in medically and surgically treated glaucoma patients: a review. Pharmaceuticals2021; 14: 581.
110.
AgnifiliLFasanellaVMastropasquaR, et al.In vivo goblet cell density as a potential indicator of glaucoma filtration surgery outcome. Investigative Opthalmology & Visual Science2016; 57: 2928.
111.
SagaraHSekiryuTNojiH, et al.Meibomian gland loss due to trabeculectomy. Jpn J Ophthalmol2014; 58: 334–341.
112.
BaiocchiSMazzottaCSgheriA, et al.In vivo confocal microscopy: qualitative investigation of the conjunctival and corneal surface in open angle glaucomatous patients undergoing the XEN-gel implant, trabeculectomy or medical therapy. Eye and Vision2020; 7: 15.
113.
KawanaKKiuchiTYasunoY, et al.Evaluation of trabeculectomy blebs using 3-dimensional Cornea and anterior segment optical coherence tomography. Ophthalmology2009; 116: 848–855.
114.
SeoJHLeeYShinJH, et al.Comparison of conjunctival vascularity changes using optical coherence tomography angiography after trabeculectomy and phacotrabeculectomy. Graefe’s Archive for Clinical and Experimental Ophthalmology2019; 257: 2239–2255.
115.
MastropasquaRBresciaLDi AntonioL, et al.Angiographic biomarkers of filtering bleb function after XEN gel implantation for glaucoma: an optical coherence tomography-angiography study. Acta Ophthalmol2020; 98: e761–e767. DOI: 10.1111/aos.14371.
116.
AkagiTOkamotoYTsujikawaA. Anterior segment OCT angiography images of avascular bleb after trabeculectomy. Ophthalmol Glaucoma2019; 2: 102.
117.
OkamotoYAkagiTKamedaT, et al.Changes in the deep vasculature assessed using anterior segment OCT angiography following trabecular meshwork targeted minimally invasive glaucoma surgery. Sci Rep2022; 12: 17187.
118.
OkamotoYAkagiTKamedaT, et al.Prediction of trabecular meshwork-targeted micro-invasive glaucoma surgery outcomes using anterior segment OCT angiography. Sci Rep2021; 11: 17850.
119.
ErbCGastUSchremmerD. German Register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefe’s Archive for Clinical and Experimental Ophthalmology2008; 246: 1593–1601.
120.
FechtnerRDGodfreyDGBudenzD, et al.Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea2010; 29: 618–621.
121.
VoicuLSalimS. New strategies for the management of ocular surface disease in glaucoma patients. Curr Opin Ophthalmol2021; 32: 134–140.
122.
AragonaP. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol2002; 86: 181–184.
123.
PflugfelderSCde PaivaCSVillarrealAL, et al.Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-β2 production. Cornea2008; 27: 64–69.
124.
VeraVSheybaniALindfieldD, et al.Recommendations for the management of elevated intraocular pressure due to bleb fibrosis after XEN gel stent implantation. Clinical Ophthalmology2019; 13: 685–694. doi:10.2147/OPTH.S195457
125.
KimJHShinYUSeongM, et al.Eyelid changes related to meibomian gland dysfunction in early middle-aged patients using topical glaucoma medications. Cornea2018; 37: 421–425.
126.
RomanowskiEGStellaNAYatesKA, et al.In vitro evaluation of a hypochlorous acid hygiene solution on established biofilms. Eye & Contact Lens: Science & Clinical Practice2018; 44: S187–S191.
127.
AnagnostopoulosAGRongAMillerD, et al.0.01% Hypochlorous acid as an alternative skin antiseptic: an in vitro comparison. Dermatol Surg2018; 44: 1489–1493.
128.
WladisEJAakaluVKFosterJA, et al.Intense pulsed light for meibomian gland disease. Ophthalmology2020; 127: 1227–1233.
129.
FrancisBASinghKLinSC, et al.Novel glaucoma procedures. Ophthalmology2011; 118: 1466–1480.
130.
SheybaniAReitsamerHAhmedIIK. Fluid dynamics of a novel micro-Fistula implant for the surgical treatment of glaucoma. Investigative Opthalmology & Visual Science2015; 56: 4789.
131.
StalmansIGillisALafautA-S, et al.Safe trabeculectomy technique: long term outcome. Br J Ophthalmol2006; 90: 44–47.
PosarelliCOrtenzioPFerrerasA, et al.Twenty-four-hour contact lens sensor monitoring of aqueous humor dynamics in surgically or medically treated glaucoma patients. J Ophthalmol2019. 2019; 2019: 9890831. DOI: 10.1155/2019/9890831.
134.
HollóGSchmidlDHommerA. Referral for first glaucoma surgery in Europe, the ReF-GS study. Eur J Ophthalmol2019; 29: 406–416.
135.
MoroiSEReedDMSandersDS, et al.Precision medicine to prevent glaucoma-related blindness. Curr Opin Ophthalmol2019; 30: 187–198.
136.
WeinrebRNFriedmanDSFechtnerRD, et al.Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol2004; 138: 458–467.
137.
GhadamzadehMKarimiFGhasemi MoghaddamS, et al.Anterior chamber angle changes in primary angle-closure glaucoma following phacoemulsification versus phacotrabeculectomy: a prospective randomized clinical trial. J Glaucoma2022; 31: 147–155.
138.
HansapinyoLChoyBNKLaiJSM, et al.Phacoemulsification versus phacotrabeculectomy in primary angle-closure glaucoma with cataract. J Glaucoma2020; 29: 15–23.
139.
MuschDCGillespieBWNiziolLM, et al.Intraocular pressure control and long-term visual field loss in the collaborative initial glaucoma treatment study. Ophthalmology2011; 118: 1766–1773.
